Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 9Neoplasms 8Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 5Esophageal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Solid Cancers 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Cholangiocarcinoma 2Breast Neoplasms 2Bites and Stings 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

Radiotherapy 4osimertinib 3aflutinib 3Radiosurgery 3Pemetrexed 3Drug Therapy 3Carboplatin 3toripalimab 2pembrolizumab 2Docetaxel 2tislelizumab 1sugemalimab 1lenvatinib 1cemiplimab 1brigatinib 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Surgical Procedures, Operative 1S 1 (combination) 1Platinum Compounds 1Platinum 1Pharmaceutical Preparations 1Paclitaxel 1Neoadjuvant Therapy 1JDQ443 1Immune Checkpoint Inhibitors 1HM781-36B 1Gemcitabine 1Diphenhydramine 1Cryotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT05615142 2026-05-11

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Sichuan University

Phase 1 Active not recruiting
9 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡